There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
None
Adult >=18 years old
with any unknown MRSA status (in centers with <15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR
which has already been shown to be MSSA
Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).
Parallel
Ertapenem
DrugAdjunctive ertapenem
Placebo
DrugSaline placebo
Clinical success
Composite of: Patient alive, fever resolved, blood cultures negative for S. aureus, systolic blood pressure \>=90mmHg not on vasopressors
Blood culture clearance
Time between first positive and first negative blood culture
Clinical improvement
Time to clinical improvement defined as the time until fever resolved, blood cultures sterile, and systolic blood pressure \>=90mmHg not on vasopressors in patients who survive to clinical improvement
Length of stay
The time from initial emergency room visit until discharge from hospital in patients discharged alive
All cause-mortality
Death from any cause
Health-related quality of life
This will be assessed using the EQ-5D-5L questionnaire
Click on the lead sponsor to view all of their trials.
Todd C. Lee MD MPH FIDSA
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor institution
